Frederike Bensch

1.5k total citations
25 papers, 585 citations indexed

About

Frederike Bensch is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Frederike Bensch has authored 25 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 16 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Frederike Bensch's work include Radiopharmaceutical Chemistry and Applications (11 papers), Medical Imaging Techniques and Applications (11 papers) and HER2/EGFR in Cancer Research (9 papers). Frederike Bensch is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (11 papers), Medical Imaging Techniques and Applications (11 papers) and HER2/EGFR in Cancer Research (9 papers). Frederike Bensch collaborates with scholars based in Netherlands, United States and Switzerland. Frederike Bensch's co-authors include Elisabeth G.E. de Vries, Marjolijn N. Lub–de Hooge, Adrienne H. Brouwers, Johan R. de Jong, Andor W.J.M. Glaudemans, Laetitia E. Lamberts, Bert van der Vegt, Carolina P. Schröder, Jourik A. Gietema and Stefan Sleijfer and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer Research.

In The Last Decade

Frederike Bensch

24 papers receiving 579 citations

Peers

Countries citing papers authored by Frederike Bensch

Since Specialization

Citations

This map shows the geographic impact of Frederike Bensch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederike Bensch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederike Bensch more than expected).

Fields of papers citing papers by Frederike Bensch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederike Bensch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederike Bensch. The network helps show where Frederike Bensch may publish in the future.

Co-authorship network of co-authors of Frederike Bensch

This figure shows the co-authorship network connecting the top 25 collaborators of Frederike Bensch. A scholar is included among the top collaborators of Frederike Bensch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederike Bensch. Frederike Bensch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases 2025 ·Lung Cancer ·(unknown), Anna Sadowska, Juliette Degens, (unknown), Frederike Bensch, (unknown), (unknown), Wouter H. van Geffen, (unknown), (unknown), Cordula Pitz, Dirk K.M. De Ruysscher, Lizza Hendriks	0
2	Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer 2024 ·Journal of Nuclear Medicine ·(unknown), (unknown), Adrienne H. Brouwers, Frederike Bensch, Sjoerd G. Elias, Evelien Kuip, Agnes Jager, Bert van der Vegt, Marjolijn N. Lub–de Hooge, Jasper Emmering, Anne I.J. Arens, Gerben J.C. Zwezerijnen, Daniëlle J. Vugts, C. Willemien Menke‐van der Houven van Oordt, (unknown), Carolina P. Schröder	11
3	Abstract PO2-13-03: Spatial HER2 heterogeneity on HER2-PET in HER2-low and negative disease: potential biomarker for antibody-drug conjugate effect 2024 ·Cancer Research ·Carolien P. Schröder, (unknown), (unknown), Adrienne H. Brouwers, Sjoerd G. Elias, Frederike Bensch, Evelien Kuip, Agnes Jager, Andor W.J.M. Glaudemans, Bert van der Vegt, C. Willemien Menke‐van der Houven van Oordt, Elisabeth G.E. de Vries	2
4	Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer 2024 ·Diagnostics ·Jorianne Boers, (unknown), Mieke C. Zwager, (unknown), Frederike Bensch, Erik F. J. de Vries, Geke A.P. Hospers, Andor W.J.M. Glaudemans, Adrienne H. Brouwers, (unknown), Sjoerd G. Elias, Evelien Kuip, Carla M.L. van Herpen, Agnes Jager, Astrid A.M. van der Veldt, Daniela E. Oprea‐Lager, (unknown), Bert van der Vegt, C. Willemien Menke‐van der Houven van Oordt, Carolina P. Schröder	3
5	Clinical utility of molecular imaging in newly diagnosed metastatic breast cancer. 2024 ·Journal of Clinical Oncology ·Carolina P. Schröder, (unknown), (unknown), Sjoerd G. Elias, Adrienne H. Brouwers, Frederike Bensch, (unknown), Lindsay Angus, Andor W.J.M. Glaudemans, Evelien Kuip, Agnes Jager, Daniela E. Oprea‐Lager, Daniëlle J. Vugts, Jasper Emmering, Anne I.J. Arens, Wim J.G. Oyen, Bert van der Vegt, (unknown), (unknown), Elisabeth G.E. de Vries	2
6	Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer During the COVID-19 Pandemic 2021 ·Clinical Lung Cancer ·(unknown), T. Jeroen N. Hiltermann, Frederike Bensch	17
7	Assessment of Bone Lesions with¹⁸F-FDG PET Compared with^99mTc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management 2020 ·Journal of Nuclear Medicine ·Suzanne C. van Es, (unknown), Sjoerd G. Elias, Frederike Bensch, Adrienne H. Brouwers, Andor W.J.M. Glaudemans, Thomas C. Kwee, (unknown), John H. Maduro, Sjoukje F. Oosting, Elisabeth G.E. de Vries, Carolina P. Schröder	13
8	Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results 2019 ·The American Journal of Surgical Pathology ·Suzanne C. van Es, Bert van der Vegt, Frederike Bensch, (unknown), (unknown), Eline Boon, Lindsay Angus, Jelle Overbosch, C. Willemien Menke‐van der Houven van Oordt, Henk M.W. Verheul, Carla M.L. van Herpen, Agnes Jager, Sjoukje F. Oosting, Elisabeth G.E. de Vries, Carolina P. Schröder	21
9	Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis 2019 ·European Journal of Nuclear Medicine and Molecular Imaging ·Yvonne W. S. Jauw, Frederike Bensch, Adrienne H. Brouwers, Otto S. Hoekstra, Josée M. Zijlstra, Simone Pieplenbosch, Carolien P. Schröder, Sonja Zweegman, Guus A.M.S. van Dongen, C. Willemien Menke‐van der Houven van Oordt, Elisabeth G.E. de Vries, Henrica C. W. de Vet, Ronald Boellaard, Marc C. Huisman	9
10	89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up 2018 ·European Journal of Nuclear Medicine and Molecular Imaging ·Frederike Bensch, Adrienne H. Brouwers, Marjolijn N. Lub–de Hooge, Johan R. de Jong, Bert van der Vegt, Stefan Sleijfer, Elisabeth G.E. de Vries, C.P. Schröder	104
11	Molecular imaging to enlighten cancer immunotherapies and underlying involved processes 2018 ·Cancer Treatment Reviews ·Elly L. van der Veen, Frederike Bensch, Andor W.J.M. Glaudemans, Marjolijn N. Lub–de Hooge, Elisabeth G.E. de Vries	31
12	Comparative biodistribution analysis across four different ⁸⁹Zr-monoclonal antibody tracers—The first step towards an imaging warehouse 2018 ·Theranostics ·Frederike Bensch, (unknown), Suzanne C. van Es, Johan R. de Jong, Carolina P. Schröder, Sjoukje F. Oosting, Marjolijn N. Lub–de Hooge, C. Willemien Menke‐van der Houven van Oordt, Adrienne H. Brouwers, Ronald Boellaard, Elisabeth G.E. de Vries	48
13	89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors 2017 ·Clinical Cancer Research ·Frederike Bensch, Laetitia E. Lamberts, (unknown), Annelies Jorritsma‐Smit, Marjolijn N. Lub–de Hooge, Anton G.T. Terwisscha van Scheltinga, Johan R. de Jong, Jourik A. Gietema, Carolien P. Schröder, Marlène Thomas, Wolfgang Jacob, K. Abiraj, Céline Adessi, Georgina Meneses‐Lorente, Ian James, Maja Weisser, Adrienne H. Brouwers, Elisabeth G.E. de Vries	57
14	⁸⁹Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment of solid tumor patients. 2016 ·Journal of Clinical Oncology ·Frederike Bensch, Laetitia E. Lamberts, (unknown), Annelies Jorritsma‐Smit, Marjolijn N. Lub–de Hooge, Anton G.T. Terwisscha van Scheltinga, Johan R. de Jong, Jourik A. Gietema, Carolina P. Schröder, Marlène Thomas, Wolfgang Jacob, K. Abiraj, Céline Adessi, Georgina Meneses‐Lorente, Ian James, Maja Weisser, Adrienne H. Brouwers, Elisabeth G.E. de Vries	1
15	ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment 2015 ·Clinical Cancer Research ·Laetitia E. Lamberts, C. Willemien Menke‐van der Houven van Oordt, (unknown), Frederike Bensch, (unknown), Johannes Voortman, Otto S. Hoekstra, Simon P. Williams, Bernard M. Fine, Daniel Maslyar, Johan R. de Jong, Jourik A. Gietema, Carolien P. Schröder, Alphons H.H. Bongaerts, Marjolijn N. Lub–de Hooge, Henk M.W. Verheul, Sandra Sanabria Bohórquez, Andor W.J.M. Glaudemans, Elisabeth G.E. de Vries	77
16	TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with ⁸⁹Zr-Fresolimumab PET 2015 ·Journal of Nuclear Medicine ·(unknown), Frederike Bensch, Andor W.J.M. Glaudemans, Thijs H. Oude Munnink, Roelien H. Enting, Wilfred F.A. den Dunnen, Mart A. A. M. Heesters, Frank A.E. Kruyt, (unknown), Jan Cees de Groot, Joseph Pearlberg, Jourik A. Gietema, Elisabeth G.E. de Vries, Annemiek Walenkamp	79
17	Abstract OT3-2-01: IMPACT: IMaging PAtients for Cancer drug selecTion – Metastatic breast cancer (MBC) 2015 ·Cancer Research ·Frederike Bensch, Adrienne H. Brouwers, Andor W.J.M. Glaudemans, Johan de Jong, Erik F. J. de Vries, (unknown), Eline Boon, Wim J.G. Oyen, Lioe‐Fee de Geus‐Oei, Eric P. Visser, (unknown), (unknown), Henk M.W. Verheul, Otto S. Hoekstra, (unknown), (unknown), Sjoerd G. Elias, (unknown), Elisabeth G.E. de Vries, Carolien P. Schröder	7
18	HER3, serious partner in crime 2014 ·Pharmacology & Therapeutics ·Arjan Kol, Anton G.T. Terwisscha van Scheltinga, Hetty Timmer‐Bosscha, Laetitia E. Lamberts, Frederike Bensch, Elisabeth G.E. de Vries, Carolina P. Schröder	52
19	A 21-Year-Old Patient With a HER2-Positive Colorectal Cancer 2014 ·Gastroenterology ·Frederike Bensch, Johan M. van Rooijen, Carolien P. Schröder, Anna K.L. Reyners	4
20	Molecular imaging for monitoring treatment response in breast cancer patients 2013 ·European Journal of Pharmacology ·Frederike Bensch, Michel van Kruchten, Laetitia E. Lamberts, Carolien P. Schröder, Geke A.P. Hospers, Adrienne H. Brouwers, Marcel A.T.M. van Vugt, Elisabeth G.E. de Vries	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact